Although the patients in this case series were on doses of a GLP-1 RA approved for treating T2DM, which are lower than the doses recommended for treating obesity, the doses used may still improve insulin sensitivity [21]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.